Introduction {#sec1-1}
============

According to the Malaysian National Cancer Registry Report for the year 2007, there was a total of 776 lymphoma cases diagnosed in the government hospitals nationwide. Lymphoma was ranked as the sixth most common cancer among males and eighth among females (NCR Report, 2007). Diffuse large B-cell lymphoma (DLBCL) is one of major subtypes of non-Hodgkin lymphoma (Hagiwara et al., 2007). It is the most common type of lymphoma among adults worldwide and it accounts for approximately 30% of all lymphoid malignancies (Lossos et al., 2004; Zainuddin et al., 2011). DLBL cases are heterogeneous in morphologic appearance, immunophenotype and biologic pattern, as well as response to chemotherapy and overall survival (Lossos et al., 2004; Hiraga et al., 2006; Yang et al., 2007; Hunt and Reichard, 2008).

DLBCL presents a high degree of genomic complexity as both somatic mutations and gross genomic alterations, such as chromosomal translocations and copy number changes of specific chromosomal regions, contribute to its pathogenesis (Testoni et al., 2015). Cell cycle deregulation, disturbances in repair of DNA damage and perturbations of transcriptional control of apoptosis are among the genetic alterations documented in DLBCL (Zainuddin et al., 2011). In addition to genetic aberrations, epigenetics changes have been implicated in the molecular pathogenesis of DLBL. As opposed to genetic mutations, epigenetic abnormalities are reversible (CHOO, 2011). Among the widely studied mechanisms it also include DNA methylation, chromatin remodelling and microRNA (CHOO, 2011). To date, DNA methylation has been shown to be the main epigenetic event taking place in lymphomagenesis leading to silencing of the tumour suppressor genes (Baylin, 2005).

*p16* (also known as CDKN2A) is a tumour suppressor gene and a member of the INK family of cyclin-dependent kinase (CDK) inhibitors located on human chromosome 9p21.3 (Lee et al., 2010; Bihl et al., 2012). *p16* protein (*p16*) is a negative cell cycle regulator involved in the blockade of G1 phase progression of the cell cycle (Khor et al., 2013). Promoter methylation of *p16* has been reported to be one of the epigenetic events contributing to the pathogenesis of DLBCL and occurring at varying frequency (Zainuddin et al., 2011). This event causes the chromatin to be inactive and leads to gene silencing during the transcriptional process (Sulewska et al., 2007; Khor et al., 2013). It is possible that inappropriate gene inactivation by DNA methylation may result in malignant transformation due to the instability of genetic environment of the transformed cells (Deep et al., 2012).

In Malaysia, Lee et al., (2010) revealed that more than 70% of the DLBCL cases in their study exhibited loss of *p16* gene as evident by monosomy 9, hemizygous and homozygous deletions. However much less is known with regard to the epigenetic alterations of *p16* gene in DLBCL cases in Malaysia (Lee et al., 2010). Therefore, this has prompted us to examine the status of *p16* methylation in DLBCL locally.

Materials and Methods {#sec1-2}
=====================

Samples {#sec2-1}
-------

Twenty-five and 63 formalin-fixed, paraffin-embedded (FFPE) tissue blocks of DLBCL cases from which diagnosis was made from year 2006 to 2013 have been retrieved from HTAA, Pahang and HUSM, Kelantan, respectively. The selection of specimens were based on the availability of completed sociodemographic data (age and gender) and the quality of extracted DNA. Overall, the archived samples were from 35 male and 53 female patients with a median age of 55 years old (range, 1-84 years). All samples were diagnosed and reconfirmed by pathologists as DLBCL according to the WHO classification. Five normal lymph node tissue blocks were also obtained from HTAA. The protocol of this study was approved by the International Islamic University Malaysia Research Ethics Committee (IREC 170) and Human Research Ethics Committee USM (USM/JEPeM/15100447).

DNA Extraction and Bisulfite Treatment {#sec2-2}
--------------------------------------

Genomic DNA was extracted from the tissue block sections using E.Z.N.A ^®^ FFPE DNA (Omega Biotek, US) kit as specified by the manufacturers. The purity and quantity of DNA was determined using NanoDrop 1000 (Thermo Scientific, US) with purity of the samples measured as 260/280 ratio in which \~1.8, was accepted as purified dsDNA.

The DNA samples were subsequently subjected to bisulfite treatment using EZ DNA Methylation-Lightning™ Kit (Zymo Research, Orange, CA) according to the manufacturers. Briefly 200-500 ng of each DNA sample was incubated with Lightning Conversion reagent at 98°C for 8 minutes and 54°C for 60 minutes. In Zymo-Spin™ IC Column, the solution was further incubated at room temperature for 20 minutes following the addition of L-Desulphonation Buffer. The bisulfite-treated DNA was then eluted in a total volume of 20 µL.

Sodium bisulfite identifies all methylated and unmethylated CpG islands present in the genome (Sulewska et al., 2007). It converts all unmethylated cytosines to uracil which is located on single-stranded DNA and leaves methylated cytosines intact (Chim et al., 2001; Nygren et al., 2005; Wang et al., 2008).

Methylation-Specific Polymerase Chain Reaction Analysis (MSP) {#sec2-3}
-------------------------------------------------------------

The methylation status at promoter region of *p16* was assessed by MSP using methylation specific primers. The primer sequences were as previously reported ([Table 1](#T1){ref-type="table"}) (Wang et al., 2008). The PCR mixture contained 10 ng of bisulfite-treated DNA, ZymoTaqTM PreMix (1X), and 0.2 µM of each primer in a final volume of 25 µL. The PCR cycling conditions were as follows: 95°C for 10 minutes; then 38 cycles at 95°C for 30 seconds, 60°C (*p16* unmethylated) or 64°C (*p16* methylated) for 40 seconds and 72°C for 40 seconds; a final extension of 7 minutes at 72°C. Human methylated and non-methylated sets (Zymo Research, Orange, CA) were used as positive and negative controls, respectively. Finally, 5 µL of the PCR products were visualised on 2% ethidium-bromide stained agarose gels under UV illumination. For each case, MSP results were recorded as methylated when a clear visible band on the agarose gel at methylated lane is observed, with or without unmethylated band.

###### 

PCR Primers of *p16* for MSP Analysis

  Genes       Primer sequences (5^'^ -\> 3^'^)   Product size (bp)
  ----------- ---------------------------------- -------------------
  *p16* M F   TTATTAGAGGGTGGGGCGGATCGC           150
  *p16* M R   GACCCCGAACCGCGACCGTAA              
  *p16* U F   TATTAGAGGGTGGGGTGGATTGT            151
  *p16* M R   CAACCCCAAACCACAACCATAA             

M, methylated; U, unmethylated; F, forward; R, reverse; bp, base pair

Statistical Analysis {#sec2-4}
--------------------

The relationship between *p16* methylation status and patients' demographic parameters was examined using Pearson's Chi-square test. The results were reported as statistically significant when p\<0.05. Confidence intervals of 95% were used to determine the effect of each variable on outcome.

Results {#sec1-3}
=======

Sixty five (65) out of 88 (74%) DLBCL samples were found to exhibit *p16* gene methylation. There was no *p16* methylation identified in the five normal lymph nodes samples. The representative results of PCR products are illustrated in [Figure 1](#F1){ref-type="fig"}. Using Pearson's Chi-square analysis, we found a significant relationship between *p16* methylation status and patients' age of \> 50 years old (p=0.04) ([Table 2](#T2){ref-type="table"}). The categorization of age is based on the study conducted by Mehrzad et al. (2014). There was no association observed between *p16* methylation status and gender ([Table 2](#T2){ref-type="table"}).

![Representative Results of Methylation-Specific PCR analysis. (a) 5, 8, 9, 10, 11 and 12, methylated; (b) 40, methylated; (c) 13, methylated; 14, unmethylated; (d) 17, unmethylated; (e) 70, unmethylated; (f) Normal lymph nodes (N1 -- N5), unmethylated. m, marker; m, methylated; u, unmethylated](APJCP-18-2781-g001){#F1}

###### 

Correlation between *p16* Gene Methylation Status and Patients' Demographic Data in DLBCL

  Characteristics   All   *p16*   
  ----------------- ----- ------- --------------------------------------
  Age                             
   ≤50 years        31    12      19
   \>50 years       57    11      46
                                  0.04[\*](#t2f1){ref-type="table-fn"}
  Gender                          
   Female           53    13      40
   Male             35    10      25
                                  0.67

Chi-square p\<0.05; M, methylated; U, unmethylated

Discussion {#sec1-4}
==========

In the present study, we have investigated a cancer-related *p16* gene methylation qualitatively using methylation-specific PCR on DLBCL specimens. Interestingly, *p16* methylation was detected at a high frequency, which was 65 (74%) out of 88 samples. To the best of our knowledge, this is the first study identifying *p16* gene methylation in DLBCL in Malaysia.

In a normal cell cycle, during the early G1 phase, retinoblastoma protein (pRb) is hypophosphorylated, while in the later phase of G1, in order for a cell to enter the S phase, pRb is progressively hyperphosphorylated by CDK4 and CDK6 (Satyanarayana and Rudolph, 2004; Li et al., 2011). The role of *p16* is observed at the point of G1-to-S phase transition in which it inactivates the kinase (CDK4 and CDK6) catalytic activities needed for phosphorylation of pRb and thereby inducing blockage of the cell cycle progression (Li et al., 2011). Methylation mediated silencing of *p16* gene might therefore trigger unregulated cell proliferation due to aggressive process of cell cycle leading to the malignant transformation and has been proposed as one of the early events in the development of lymphoid malignancies (Takino et al., 2005). There also appears to be evidence supporting the role for *p16* inactivation in the transformation of low-growth fraction lymphomas into their aggressive variants (Baur et al., 1999; Huang et al., 2004). Takino et al., (2005) documented *p16* loss due to methylation in MALT lymphoma (60%) with transformation to DLBCL. In essence, the role of aberrant DNA methylation in the pathogenesis of DLBCL would require further comprehension of the biochemical and biological effects of epigenetic modifications on lymphomagenesis (Shaknovich and Curr, 2011). Also, as epigenetic abnormalities are reversible, further understanding of *p16* methylation role in the pathogenesis of DLBCL could pave the way for a targeted therapeutic intervention.

*p16* silencing event through methylation in non-Hodgkin lymphoma occurs in a varied frequency ranging from 9% to 72% (Zainuddin et al., 2011). Guney et al., (2012) showed that *p16* inactivation by deletion or methylation was observed in 42.7% of DLBCL cases studied while Zainuddin et al., (2011) revealed *p16* methylation in 37% of their cases. In this present study, a higher percentage of DLBCL cases (74%) with *p16* methylation was obtained. As we only performed qualitative assessment of the *p16* promoter region methylation, it is possible that the number of positive DLBCL cases could be higher if a quantitative technique such as pyrosequencing is employed in determining the methylation status of this gene as shown by Zainuddin et al., (2011).

Interestingly, we also found statistical significant association between *p16* methylation status and patients aged of more than 50 years old. There was a number of researchers associating *p16* methylation in cancer and the age of patients. However, we could not find similar studies which highlight on the evidence of *p16* methylation and older age in human DLBCL, except for a study by Alhejaily et al., (2014) in follicular lymphoma patients, where CDKN2A deletion or methylation was found to be associated with more advanced age. Aging is known to be an important risk factor in the development of cancers (Ahuja et al., 1998) and we speculate that this might be due to the increased transformation of malignant cells in aging cell population. The process of cellular senescence which causes irreversible growth arrest can be triggered by multiple mechanisms; one of which is epigenetic depression of *p16* which in turn serves as an excellent molecular marker of aging (Collado et al., 2007). It is also noteworthy that *p16* gene methylation is not the sole determinant of *p16* expression (Keyes et al., 2007). DNA-damages, oxygen radicals, ionizing radiation, chemotherapeutic agents and telomere dysfunction including molecular positive regulator of ERK-mediated activation of Ets1/2 are known to cause *p16* elevation (Kim and Sharpless, 2006).

Although *p16* promoter methylation occurs in DLBCL and may be one of the significant events in human lymphomagenesis, its role as a biomarker for diagnostic of accuracy will need to be further studied (Guney et al., 2012). Amara et al., (2008) found that hypermethylated *p16* of DLBCL was associated with a more aggressive disease and poorer outcome, whereas Zainuddin et al., (2011) questioned its role as a negative factor. We, however in this study, were not able to investigate on the impact of *p16* methylation on the clinical outcomes of our patients due to lack of data. In addition, as there appears to be a good agreement of *p16* methylation with lack of protein expression in B-cell lymphomas (Huang et al., 2004), further research to examine on *p16* expression along with *p16* methylation is highly recommended.

As far, the current study has demonstrated the highest occurrence of *p16* methylation in DLBCL cases obtained from two medical institutions located in the East Coast of Malaysia, and this was achieved using the MSP technique. It indicates that the contribution of *p16* tumour suppressor methylation in DLBCL development might be of high importance. There might be an increased transformation of malignant cells in the aging cell population, as we have found a significant increase in *p16* methylation among patients aged 50 years and above. Moreover, this valuable discovery is supported by the absence of *p16* methylation observed in five normal lymph node tissue samples. Nevertheless, due to the lack of complete clinical data of all patients, we were unable to confirm on the diagnostic or prognostic values of *p16* methylation in our DLBCL samples. Therefore, more research related to quantitative evaluation of *p16* methylation, the mRNA and protein expression, as well as the correlation to clinicopathological parameters are needed as *p16* might be a valuable prognostic biomarker for DLBCL in Malaysia. Other pathways involved in the *p16* DNA methylation-related metastasis phenotype are also worth to be explored.
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